Your browser doesn't support javascript.
loading
Margetuximab: An active alternative for later-line therapy in patients with HER2-positive advanced breast cancer.
Zhou, Yunxiang; Wang, Xiaojia; Chen, Yiding.
Afiliación
  • Zhou Y; Department of Breast Surgery and Oncology The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
  • Wang X; Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
  • Chen Y; Department of Breast Medical Oncology The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences Hangzhou Zhejiang China.
MedComm (2020) ; 4(4): e322, 2023 Aug.
Article en En | MEDLINE | ID: mdl-37409110
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MedComm (2020) Año: 2023 Tipo del documento: Article Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MedComm (2020) Año: 2023 Tipo del documento: Article Pais de publicación: China